It has been an exciting year for Amphivena Threrapeutics. The company developed several promising advances in cancer immunotherapies. One of the most notable of these is AMV564, the company’s proprietary T-cell redirecting bispecific CD33/CD3 antibody. The United States Fod and Drug Administration accepted the investigative drug and it will began to be given to Leukemia patients.
While AMV564 is only in phase one of the investigative process, Jeanmarie Guenot, Ph.D., the president and chief executive officer of Amphivena Therapeutics, is positive that it will bring promising news to the pharmaceutical industry. She believes that this first phase will open several new treatment options for medical professionals and cancer patients.
“Our preclinical program demonstrated impressive cytotoxic activity in AML patient samples and animal models that was both potent and selective,” Guenot explained in a press release. “This is suggesting the potential for a robust therapeutic response with minimal off-target safety concerns.”
Guenot looks forward to beginning the clinical phase of testing and is optimistic about the future of Amphivena Therapeutics. The company believes that this therapy treatment has huge potential to change the way cancer is approached.
JeanMarie Guenot further explains that AMV564 aims to eliminate cancer cells in the body, including the bine, marrow and blood. If phase one goes as plan, AMV564 could be headed to clinical trials very soon.
Guenot is no stranger to this industry. In fact, she has more than twenty years in the pharmaceutical and biotechnology industry. Her leadership of the San Francisco based, Amphivena Therapeutics has been a highlight of her career. With such promising advancement being made, Guenot and Amphivena Therapeutics have been featured by several major news outlets, such as News on 6.
The future looks extremely bright for this successful oncology startup company whose mission is to eliminate the presence of blood cancers and provide a cure to those it has affected.